MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex
Links shared publicly online about this topic.
- 101total visits
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex
View full resource at drugs.com
Tags: Migraine Medication, Drug, Pharma, FDA, DHE 45, Migranal Nasal Spray, Nature
Most Recently Shared on August 2, 2011 at 11:08 pm By:
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for Levadex: MOUNTAIN VIEW, Calif., Aug. 2,... http://bit.ly/pR77XD #drug
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® - MarketWatch
marketwatch.com — “MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on August 2, 2011 at 2:56 pm By:
John Carroll Health Communicator
Novo Nordisk is hiring and blueprinting a new US HQ in Jersey. http://bit.ly/nYdvlP
NDA Accepted for Levadex for Migraine - MPR
empr.com — “MAP Pharmaceuticals announced that the FDA has accepted its new drug application (NDA) of Levadex for the potential acute treatment of migraine in adults.” View full resource at empr.com
Most Recently Shared on August 2, 2011 at 2:00 pm By:
MPR News: NDA Accepted for Levadex for Migraine: MAP Pharmaceuticals announced that the FDA has accepted its new... http://bit.ly/oY8aXL
Advertisement
